A Superiority Study of Model-Guided Optimized Dosing Versus Empirical Dosing of Piperacillin/Tazobactam in the Treatment of Community-Acquired Pneumonia in Elderly Patients
Key facts
- Who runs it
- Shandong University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 118 people, planned
- Started
- 17 Jul 2026
- Expected to end
- 31 May 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®)
- Record updated
- 18 November 2026
Who can take part
- Age
- 65 years to 110 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (15)Hide the full registry criteria
Who can take part
- Age ≥ 65 years
- Clinically diagnosed or highly suspected community-acquired pneumonia (CAP). CAP clinical diagnostic criteria: All three of the following must be met:; Onset in the community setting; At least one of the following clinical manifestations:; New-onset cough, sputum production, or worsening of pre-existing respiratory symptoms, with or without purulent sputum, chest pain, dyspnea, or hemoptysis; Fever; Signs of pulmonary consolidation and/or moist rales; Peripheral white blood cell count > 10×10⁹/L or < 4×10⁹/L, with or without left shift; Chest imaging showing new patchy infiltrates, lobar/segmental consolidation, ground-glass opacities, or interstitial changes, with or without pleural effusion; For patients aged ≥ 65 years with a body temperature < 38°C, the presence of clear clinical signs of pneumonia and abnormal chest X-ray findings will also be considered meeting the inclusion criteria
- At least one of the following risk factors for drug-resistant pathogens:; Comorbidities such as chronic cardiopulmonary disease, diabetes mellitus, renal failure, etc.; Use of broad-spectrum antibiotics within the past 3 months; History of repeated hospitalizations or residence in a long-term care facility
- Patients are required to initiate intravenous empiric antimicrobial therapy, and piperacillin-tazobactam is considered appropriate empiric treatment
- Expected length of hospital stay ≥ 72 hours
- Signed informed consent form
Who cannot take part
- Concurrent use of broad-spectrum antibiotics with similar antibacterial spectra, including cefoperazone-sulbactam, imipenem-cilastatin, meropenem, biapenem and others
- Patients with severe allergy to β-lactams and history of severe adverse reactions
- End-stage diseases with expected survival time shorter than the treatment course, such as advanced malignant tumors and end-stage organ failure
- Any other conditions deemed ineligible for enrollment by investigators; Post-randomization exclusion criteria:
- Isolated fungal infection
- Isolated viral infection
- Severe renal insufficiency with creatinine clearance <40 mL/min, or patients receiving continuous renal replacement therapy (CRRT)
- Highly suspected or confirmed fungal pneumonia or viral pneumonia
- Patients with confirmed pathogenic bacteria resistant to piperacillin-tazobactam (PIP/TAZO) during the study
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- PD target attainment rate or pneumonia or elderly
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study tests a new way to give an antibiotic to older adults with pneumonia. Pneumonia is a lung infection.
Read full original descriptionShow less
Piperacillin-tazobactam is an antibiotic. Doctors often use it to treat pneumonia in older adults. Right now, doctors usually give this drug every 8 hours. They let it drip into the vein over 3 hours.
But early research suggests a different schedule may work better. This study will test giving the drug every 6 hours. The drip will last 4 hours. Researchers think this may help the drug fight germs better.
The study will compare the usual schedule with the new schedule. Participants will join one of two groups. One group will get the usual schedule. The other group will get the new schedule.
Researchers will check how well the drug works. They will also watch for side effects. They want to find the safest and most helpful way to give this drug.
Adults aged 65 and older with community-acquired pneumonia can join. Community-acquired pneumonia is a lung infection that starts outside of a hospital.
The 2 groups in the trial
- guideline-based conventional dosingExisting treatment, for comparison
Treatment: Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®)
- Model-guided optimized dosingTreatment being tested
Treatment: Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®)
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Superiority Study Comparing Model-Guided Optimized Dosing With Empirical Dosing of Piperacillin/Tazobactam in Elderly Patients With Community-Acquired Pneumonia
- Criteria questions
- Built from NCT07945275, who can take part
- Record updated
- 18 November 2026